These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30379598)

  • 1. Redirected T Cell Cytotoxicity in Cancer Therapy.
    Clynes RA; Desjarlais JR
    Annu Rev Med; 2019 Jan; 70():437-450. PubMed ID: 30379598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
    Satta A; Grazia G; Caroli F; Frigerio B; Di Nicola M; Raspagliesi F; Mezzanzanica D; Zaffaroni N; Gianni AM; Anichini A; Figini M
    Front Immunol; 2019; 10():2514. PubMed ID: 31708930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics.
    Kamperschroer C; Shenton J; Lebrec H; Leighton JK; Moore PA; Thomas O
    J Immunotoxicol; 2020 Dec; 17(1):67-85. PubMed ID: 32100588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
    Zhukovsky EA; Morse RJ; Maus MV
    Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
    PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
    Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
    MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
    Rossi EA; Rossi DL; Cardillo TM; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2014 Oct; 13(10):2341-51. PubMed ID: 25053819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
    Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
    J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies and diabodies for cancer immunotherapy.
    Elsässer-Beile U; Bühler P
    Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
    [No Abstract]   [Full Text] [Related]  

  • 19. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
    Maletz K; Kufer P; Mack M; Raum T; Pantel K; Riethmüller G; Gruber R
    Int J Cancer; 2001 Aug; 93(3):409-16. PubMed ID: 11433407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
    Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.